Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2023-07-27T16:31:08Z | - |
dc.date.available | 2023-07-27T16:31:08Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2044-5385 | * |
dc.identifier.other | OAK-33777 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265136 | - |
dc.description.abstract | This study aimed to identify the benefits of autologous-stem cell transplantation (auto-SCT) and allogeneic-SCT (allo-SCT) in patients with aggressive T-cell lymphomas to aid in the selection of transplantation type in clinical practice. This study retrospectively analyzed data from 598 patients who underwent transplantation for T-cell lymphomas from 2010 to 2020. In total, 317 patients underwent up-front SCT as consolidation therapy. The 3-year progression-free survival (PFS) and overall survival (OS) were 68.7% and 76.1%, respectively. Patients who underwent auto-SCT had significantly better OS (p = 0.026) than those who underwent allo-SCT; however, no statistical difference in PFS was found. Transplantation was used as a salvage therapy in 188 patients who had relapsed/refractory disease. Overall, 96 (51.1%) patients underwent auto-SCT and 92 (48.9%) patients underwent allo-SCT. Auto-SCT improved long-term survival in patients with complete remission (CR). Allo-SCT demonstrated better 3-year PFS in patients with partial remission and relapsed/refractory disease status. However, >50% of patients died within 1 year of allo-SCT. As a consolidative therapy, up-front auto-SCT demonstrated a survival benefit. Auto-SCT was also effective in patients who achieved CR after salvage therapy. If the disease persists or cannot be controlled, allo-SCT may be considered with reduced intensity conditioning. © 2023, The Author(s). | * |
dc.language | English | * |
dc.publisher | Springer Nature | * |
dc.title | Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 13 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Blood Cancer Journal | * |
dc.identifier.doi | 10.1038/s41408-023-00868-w | * |
dc.identifier.wosid | WOS:001020604200003 | * |
dc.identifier.scopusid | 2-s2.0-85163382093 | * |
dc.author.google | Baek | * |
dc.author.google | Dong Won | * |
dc.author.google | Moon | * |
dc.author.google | Joon Ho | * |
dc.author.google | Lee | * |
dc.author.google | Jae Hoon | * |
dc.author.google | Kang | * |
dc.author.google | Ka-Won | * |
dc.author.google | Ho Sup | * |
dc.author.google | Eom | * |
dc.author.google | Hyeon-Seok | * |
dc.author.google | Enuyoung | * |
dc.author.google | Ji Hyun | * |
dc.author.google | Jeong-Ok | * |
dc.author.google | Park | * |
dc.author.google | Seong Kyu | * |
dc.author.google | Kim | * |
dc.author.google | Seok Jin | * |
dc.author.google | Yoo | * |
dc.author.google | Keon Hee | * |
dc.author.google | Yoon | * |
dc.author.google | Sung-Soo | * |
dc.author.google | Koh | * |
dc.author.google | Youngil | * |
dc.author.google | Hyoung Jin | * |
dc.author.google | Won | * |
dc.author.google | Jong-Ho | * |
dc.author.google | Lyu | * |
dc.author.google | Chuhl Joo | * |
dc.author.google | Hahn | * |
dc.author.google | Seung Min | * |
dc.author.google | Jung-Hee | * |
dc.author.google | Joon Seong | * |
dc.author.google | Jo | * |
dc.author.google | Jae-Cheol | * |
dc.author.google | Mun | * |
dc.author.google | Yeung-Chul | * |
dc.author.google | Yang | * |
dc.author.google | Deok-Hwan | * |
dc.author.google | Song | * |
dc.author.google | Ga-Young | * |
dc.author.google | Lim | * |
dc.author.google | Sung-Nam | * |
dc.author.google | Sohn | * |
dc.author.google | Sang Kyun | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |